trending Market Intelligence /marketintelligence/en/news-insights/trending/PM9_Mx8i8D_XSsNo8Bm85w2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Arvinas prostate cancer drug gets US FDA fast-track status


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Arvinas prostate cancer drug gets US FDA fast-track status

Arvinas Inc. said the U.S. Food and Drug Administration has granted fast-track designation to ARV-110, an investigational drug for treating men with a certain type of prostate cancer.

The New Haven, Conn.-based company is evaluating the safety and efficacy of ARV-110 in an early-stage study involving male patients with castration-resistant prostate cancer that has spread to other parts of the body and whose disease progressed after receiving two or more systemic therapies.

Prostate cancer is the second-most prevalent cancer in men as well as the second leading cause of death in men in the U.S. The American Cancer Society predicts that one in nine men will be diagnosed with prostate cancer during their lifetime.

Full results of the trial are expected to be available in the first half of 2020.